Overview of the impact of conventional systemic therapies on breast cancer

被引：12
|
作者：
Howell, A [1 ]
Wardley, AM [1 ]
机构：
[1] Univ Manchester, Christie Hosp, CRUK Dept Med Oncol, Manchester M20 4BX, Lancs, England
来源：
ENDOCRINE-RELATED CANCER | 2005年 / 12卷
关键词：
D O I：
10.1677/erc.1.01003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Survival in women with breast cancer is improving in the western world, in part related to improved surgery, radiotherapy and adjuvant systemic therapy. Aromatase inhibitors are superior to tamoxifen in this clinical situation and several studies indicate that taxane-based chemotherapy is superior to non-taxane-based regimens. Herceptin is active alone in HER-2/neu +ve advanced breast cancer and four clinical trials are testing this agent in the adjuvant situation. It seems likely that herceptin will add to conventional therapies and thus will be the paradigm for the introduction of other biological therapies to improve cure rates.
引用
收藏
页码：S9 / S16
页数：8
相关论文
共 50 条
  • [21] Triple negative breast cancer: proven and promising systemic therapies
    Bergin, Alice
    Oakman, Catherine
    Lindeman, Geoffrey J.
    CANCER FORUM, 2016, 40 (03) : 20 - 25
  • [22] Achievements in systemic therapies in the pregenomic era in metastatic breast cancer
    Colozza, Mariantonietta
    de Azambuja, Evandro
    Personeni, Nicola
    Lebrun, Fabienne
    Piccart, Martine J.
    Cardoso, Fatima
    ONCOLOGIST, 2007, 12 (03): : 253 - 270
  • [23] The use of complementary therapies by breast cancer patients attending conventional treatment
    Crocetti, E
    Crotti, N
    Feltrin, A
    Ponton, P
    Geddes, M
    Buiatti, E
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (03) : 324 - 328
  • [24] Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer
    Guler, Ezgi
    Smith, Daniel A.
    Somarouthu, Bhanusupriya
    Gujrathi, Rahul
    Ramaiya, Nikhil H.
    Tirumani, Sree Harsha
    ABDOMINAL RADIOLOGY, 2020, 45 (03) : 828 - 841
  • [25] Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer
    Ezgi Guler
    Daniel A. Smith
    Bhanusupriya Somarouthu
    Rahul Gujrathi
    Nikhil H. Ramaiya
    Sree Harsha Tirumani
    Abdominal Radiology, 2020, 45 : 828 - 841
  • [26] Impact of Integrative Therapies on Patients with Metastatic Breast Cancer
    Andac-Jones, Elif
    Gonzalo, Maria B.
    Kelly, Gail
    Weldon, Susan
    CANCER RESEARCH, 2023, 83 (05)
  • [27] Overview of adjuvant systemic therapy in early stage breast cancer
    Newman, Lisa A.
    Singletary, S. Eva
    SURGICAL CLINICS OF NORTH AMERICA, 2007, 87 (02) : 499 - +
  • [28] Impact of neoadjuvant systemic therapies on axillary response in early-stage triple-negative breast cancer
    Kook, Y.
    Minji, L.
    Moon, S.
    Ho, B. Seung
    Bae, S. J.
    Jeong, J.
    Ahn, S. G.
    ANNALS OF ONCOLOGY, 2024, 35 : S1408 - S1408
  • [29] Integration of novel targeted therapies into the systemic treatment of breast cancer - a review
    Tsakonas, G.
    Kosmas, C.
    JOURNAL OF BUON, 2007, 12 (03): : 319 - 327
  • [30] Systemic treatment of breast cancer New insights into neoadjuvant and adjuvant therapies
    Ditsch, N.
    Untch, M.
    ONKOLOGE, 2022, 28 (01): : 77 - 90
12345